Japan-based Mochida Pharmaceutical (Mochida) announced on 25 November 2021 that its adalimumab biosimilar had been launched in Japan following the listing of the drug on the National Health Insurance (NHI).
Adalimumab biosimilar launched in Japan
Biosimilars/News | Posted 03/12/2021 0 Post your comment
Adalimumab is a human monoclonal antibody that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF), a soluble inflammatory cytokine. Adalimumab binds to TNF-alpha (TNF-α), preventing it from activating TNF receptors, which cause the inflammatory reactions associated with autoimmune diseases. Adalimumab is indicated for the treatment of rheumatoid, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis.
Mochida says that Adalimumab BS MA [adalimumab biosimilar 3], which was developed in Japan, is the first 80 mg syringe preparation of an adalimumab biosimilar in the country. The company adds that all types of preparation are available for self injection.
Adalimumab BS MA was launched as the first adalimumab biosimilar which contains the same concentration of active ingredient as the originator adalimumab, Humira, which is currently distributed in Japan.
Mochida signed a deal to co-develop and commercialize an adalimumab biosimilar for the Japanese market with South Korea-based LG Life Sciences back in 2014 . Mochida now has a collaboration agreement with AYUMI, who will distribute and promote Adalimumab BS MA in Japan for indications in the field of gastroenterology.
Mochida and AYUMI are also collaborating on the commercialization of Etanercept BS MA [etanercept biosimilar 1], which was approved in Japan in January 2018  and launched in May 2018.
Adalimumab BS MA is Mochida’s third biosimilar approved in Japan. In addition to adalimumab and etanercept, the company also has a teriparatide biosimilar, Teriparatide BS [teriparatide biosimilar 1], approved in Japan .
Biosimilars of adalimumab
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.
View this week’s headline article: La evidencia sobre la sustitución automática de biológicos es limitada
Browse the news in the Latin American Forum!
LATIN AMERICAN FORUM
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.
Vea el artículo principal de esta semana: La evidencia sobre la sustitución automática de biológicos es limitada
Explore las noticias en el Foro Latinoamericano!
1. GaBI Online - Generics and Biosimilars Initiative. LG Life Sciences and Mochida make deal for adalimumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Dec 3]. Available from: www.gabionline.net/biosimilars/news/LG-Life-Sciences-and-Mochida-make-deal-for-adalimumab-biosimilar
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Dec 3]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-approved-in-Japan
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.